
The Global approvals for #Icotyde continue to expand. Hearty Congrats to all involved in the journey. Cheers!
Protagonist is very pleased to see another global approval for ICOTYDE™ (icotrokinra)! ICOTYDE, co-discovered by Protagonist and Johnson & Johnson scientists, has now been approved in the United Kingdom for adults and adolescents with moderate-to-severe plaque psoriasis. This latest approval builds on approvals in the U.S., China, and EU, bringing ICOTYDE to more patients around the world. gov.uk/government/news/mhra-… #ICOTYDE #PeptideTherapeutics #PTGX










